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Abstract
Introduction Expression of the A and B forms of progesterone
receptor (PR) in an appropriate ratio is critical for mammary
development. Mammary glands of PR-A transgenic mice,
carrying an additional A form of PR as a transgene, exhibit
morphological features associated with the development of
mammary tumors. Our objective was to determine the roles of
estrogen (E) and progesterone (P) in the genesis of mammary
hyperplasias/preneoplasias in PR-A transgenics.
Methods We subjected PR-A mice to hormonal treatments and
analyzed mammary glands for the presence of hyperplasias and
used BrdU incorporation to measure proliferation. Quantitative
image analysis was carried out to compare levels of latency-
associated peptide and transforming growth factor beta 1
(TGF1) between PR-A and PR-B transgenics. Basement
membrane disruption was examined by immunofluorescence
and proteolytic activity by zymography.
Results The hyperplastic phenotype of PR-A transgenics is
inhibited by ovariectomy, and is reversed by treatment with E +
P. Studies using the antiestrogen ICI 182,780 or antiprogestins
RU486 or ZK 98,299 show that the increase in proliferation
requires signaling through E/estrogen receptor alpha but is not
sufficient to give rise to hyperplasias, whereas signaling through
P/PR has little impact on proliferation but is essential for the
manifestation of hyperplasias. Increased proliferation is
correlated with decreased TGF1 activation in the PR-A
transgenics. Analysis of basement membrane integrity showed
loss of laminin-5, collagen III and collagen IV in mammary glands
of PR-A mice, which is restored by ovariectomy. Examination of
matrix metalloproteases (MMPs) showed that total levels of
MMP-2 correlate with the steady-state levels of PR, and that
areas of laminin-5 loss coincide with those of activation of MMP-
2 in PR-A transgenics. Activation of MMP-2 is dependent on
treatment with E and P in ovariectomized wild-type mice, but is
achieved only by treatment with P in PR-A mice.
Conclusions These data establish a link between hormonal
response, proliferation, modulation of MMP activity and
maintenance of basement membrane integrity that depend on a
balance in the expression levels of PR-A and PR-B isoforms.
Notably, concomitant increased proliferation, due to inhibition of
TGF1 activation, and loss of basement membrane integrity, via
increased MMP-2 activity, appear to be prerequisites for the PR-
A hyperplastic phenotype.
Introduction
Progesterone receptor (PR) belongs to the superfamily of ster-
oid receptors and mediates the action of progesterone in its
target tissues [1,2]. In both humans and rodents, progester-
one promotes the proliferation of epithelial cells that accompa-
nies each menstrual/estrous cycle and pregnancy. In normal
mammary glands of adult human and rodent females, PR
expression is restricted to the luminal epithelial cells of the
BM: basement membrane; BrdU: 5-bromo-2-deoxyuridine; ECM: extracellular matrix; ER: estrogen receptor; FCS: fetal calf serum; H&E: hematoxylin 
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duct [3]. Studies on PR-null mutant mice have revealed that
PR is essential for progesterone-dependent proliferation of
epithelial cells [4].
PR exists in two isoforms, the A and B forms, and the expres-
sion of these, in an appropriate ratio, is critical for normal mam-
mary development [5]. As such, mammary development is
abnormal in transgenic mice carrying either an additional A
form of PR (PR-A transgenics) or the B form of PR (PR-B
transgenics) [6,7]. In particular, mammary glands of PR-A
transgenics are characterized by extensive lateral branching,
ductal hyperplasia, a disorganized basement membrane (BM)
and loss of cell-cell adhesion [6]. Studies using the molecular
markers for transformation, as defined by Medina [8], revealed
that these mammary glands contained at least two distinct
populations of transformed epithelial cells. The ducts with nor-
mal histology contain cells resembling immortalized cells,
while hyperplasias consist of cells in later stages of transfor-
mation associated with early preneoplasias [9].
The development of cancer is also associated with disruption
of tissue architecture. Branching morphogenesis in the mam-
mary gland is the culmination of hormone-mediated prolifera-
tion and extracellular matrix (ECM) remodeling; these are each
in turn dependent on the production of growth factors and the
balance between ECM production and degradation [10].
Once established, the mammary gland undergoes rounds of
highly orchestrated proliferation and morphogenesis during
pregnancy and involution, yet without losing the fundamental
patterning of the gland. In contrast, hyperplasia is defined as
loss of this patterning and is considered to be a precursor to
neoplasia.
It is well established that PR-A can modulate the activities of
both estrogen receptor (ER) alpha and PR [11,12]. Accord-
ingly, either estrogen action or progesterone action or both,
resulting from overexpression of PR-A, may mediate the abnor-
mal mammary phenotype of PR-A transgenics. To this end, the
objective of our present study was to identify the respective
roles of estrogen and progesterone in the genesis of mammary
hyperplasias/preneoplasias in PR-A transgenic mice.
Materials and methods
Mice, treatment with steroids and tissue preparations
All mice used in these studies were of FVB strain. The mice
were housed and cared for in accordance with the National
Institutes of Health guide to humane use of animals in
research. All experiments were conducted with Lawrence Ber-
keley National Laboratory institutional review and approval.
Animals were killed by carbon dioxide inhalation and cervical
dislocation at the indicated times in accordance with Associa-
tion for Assessment and Accreditation of Laboratory Animal
Care guidelines.
PR-A transgenic mice [6] and PR null mutant mice [4] have
been described previously. Nulliparous adult (9 to 12 weeks
old) mice were used either intact or ovariectomized and/or
treated with steroids for the indicated times. For zymography
studies, prior to tissue collection, mice were perfused with 10
ml PBS and the tissues were frozen in liquid nitrogen and
stored at -70°C until use.
For studies with steroids, nulliparous adult mice were used
either as intact or after ovariectomy. Estradiol (1 g/mouse)
and/or progesterone (1 mg/mouse) were administered as
described previously [3]. Antiestrogen, ICI 182,780 (50 g/
mouse; Tocris Cookson Inc., Ellisville, MO, USA) or antipro-
gestin, mifepristone (RU486, 16 g/g body weight; Sigma, St
Louis, MO, USA) or ZK 98,299 (16 g/g body weight; gift
from Dr Ming-Wei Wang) were administrated daily for 4 days.
For cell proliferation studies, mice were administered 160 g/
g body weight 5-bromo-2-deoxyuridine (BrdU) (Sigma) 2
hours prior to sacrifice.
For mammary whole mounts, one of the Number 4 inguinal
mammary glands was fixed in Carnoy's solution and stained in
Alum Carmine [0.2% carmine/0.5% aluminum potassium sul-
fate (both from Sigma, St Louis, MO, USA)]. For immunohisto-
chemical analyses on paraffin sections, mammary tissues were
collected, fixed in 4.7% buffered formalin (Fisher Scientific,
Pittsburgh, PA, USA), dehydrated, embedded in paraffin and
cut into 5 m thick sections. For immunofluorescence analy-
ses on frozen sections, the entire Number 4 inguinal mammary
glands were mounted and quick-frozen in Optimal Cutting
Temperature compound (Ted Pella, Inc., Redding, CA, USA).
Cryostat sections (5 to 10 m thick) were cut and mounted
onto glass slides and were fixed for 2 minutes in methanol/
acetone (1:1).
Antibodies
The antibodies used were: anti-BrdU, rat monoclonal antibody
(Harlan Sera-Lab Ltd, Loughborough, UK); goat anti-latency-
associated peptide (anti-LAP) and chicken anti-transforming
growth factor beta 1 (anti-TGF1) (R&D Systems, Minneapo-
lis, MN, USA); MMP-2 (Millipore, Bilerica, MA, USA); collagen
I, collagen III and collagen IV (Southern Biotechnology Assoc.
Inc., Birmingham, AL, USA); laminin-1 (Telios Pharmaceuti-
cals, San Diego, CA, USA); and laminin-5 (gift from Dr V
Quaranta).
Immunohistochemistry and immunofluorescence
BrdU-positive cells were analyzed in paraffin-embedded sec-
tions as described previously [9]. Briefly, paraffin sections
were deparaffinized and rehydrated prior to antigen retrieval
and treatment with specified antibodies. The antigen-antibody
complexes were identified using the Universal DAKO LSAB2-
labeled streptavidin-biotin peroxidase kit (DAKO, Carpinteria,
CA, USA). The sections were counterstained with Mayer's
hematoxylin solution (DAKO). After counterstaining, nucleiAvailable online http://breast-cancer-research.com/content/11/5/R72
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negative for the antigen appeared purple-blue and positive
nuclei appeared brown.
Immunofluorescence assays were performed as described
previously [3]. Briefly, nonspecific binding sites were blocked
by incubation in a blocking buffer (PBS containing either 1%
casein or 15% FCS and 0.2% Tween 20), for 30 minutes at
ambient temperature. Sections were then treated with primary
antibodies, washed with PBS and incubated with fluorescein
isothiocyanate-conjugated secondary antibodies (dissolved in
the blocking buffer) for 30 minutes at ambient temperature.
Slides were then washed five times with PBS and the nuclei
were stained with 4',6-diamino-2-phenylindole and mounted
with Vectashield (Vector Laboratories, Burlingame, CA, USA).
Image acquisition and processing
Immunofluorescence images were obtained using a 40 × 0.75
numerical aperture Zeiss Neofluor objective on a Zeiss Axio-
vert equipped with epifluorescence (Carl Zeiss MicroImaging,
Inc., Thornwood, NY, USA). A multiband-pass dichroic mirror,
barrier filter and differential wavelength filter wheel combina-
tion was used to selectively excite fluorochromes in sequence.
Images were captured using a scientific-grade 12-bit charged
coupled device (KAF-1400, 1,317 × 1,035, 6.8 m square
pixels) on a Xillix digital camera (Vancouver, Canada). Relative
intensity of images was maintained when constructing figures
using Scilimage (TNO Institute of Applied Physics, Delft, the
Netherlands) to scale the 12-bit data to a common 8-bit scale
using the dataset minimum and maximum. False color was
assigned accordingly. Internal standardization was achieved
by comparing only images stained with the same antibodies in
the same experiment, captured with identical parameters and
scaled and displayed identically.
Zymography
Mammary glands were homogenized on ice in RIPA insoluble
buffer (50 mM Tris, pH 8.0, containing 150 mM NaCl, 0.1%
sodium dodecyl sulfate, 0.5% deoxycholate and 1% NP40).
The homogenates were centrifuged for 15 minutes at 4°C and
the supernatants were subjected to electrophoresis on gelatin
substrate gels (8.8% sodium dodecyl sulfate-polyacrylamide
slab gels containing 1 mg/ml gelatin), as described previously
[13]. Subsequently, the gels were treated with 2.5% Triton X-
100 for 30 minutes, followed by incubation for 24 hours at
37°C in a buffer containing 100 mM Tris- HCl, pH 7.4, and 15
mM CaCl2. The gels were stained with Coomassie Blue R-250
and destained with water until clear zones indicative of prote-
olytic activity emerged against a blue background. The zymo-
grams were scanned and subjected to densitometric analyses
using the PC version of NIH image (Scion Corporation, Fred-
erick, MD, USA).
Statistical analysis
The data are presented as the mean ± standard error of the
mean. The differences between the various experimental
groups were analyzed by Student's t test and were considered
significant when P < 0.05 was obtained. A Kolmogorov-Smir-
nov comparison of two datasets was used to compare the
TGF1 and LAP data, with P < 0.05 considered significant.
Results
Mammary phenotype of PR-A transgenics is dependent 
on ovarian steroids
We previously showed that the mammary glands of adult PR-
A transgenic mice are characterized by extensive lateral
branching and the presence of very thick ducts [6]. Histologi-
cal analyses revealed that the thickening of the duct walls was
due to the presence of multiple layers of cells, in contrast to
the monolayer or simple epithelium found in ducts of wild-type
mice [6]. These hyperplasias were characterized by a disrup-
tion of the basement membrane and loss of cell-cell adhesion
[6].
The morphology of the mammary glands of PR-A transgenics
under different hormonal conditions is shown in Figure 1. The
excessive ductal side branching in glands of adult females
(Figure 1a) was abolished upon ovariectomy (Figure 1b).
Short-term administration of estradiol alone initiated epithelial
proliferation, characterized by the presence of numerous side
buds (Figure 1c); however, when progesterone was adminis-
tered with estradiol, the effects of ovariectomy on the PR-A
phenotype was fully reversed such that the hyperplastic mam-
mary phenotype resembled that of intact mice (Figure 1, com-
pare a and d).
To identify the relative importance of signaling through estro-
gen versus progesterone in eliciting the excessive ductal
growth, intact mice were treated with either antiestrogen ICI
182,780 or antiprogestins RU486 or ZK 98,299. Surprisingly,
in mammary glands of mice treated with ICI 182,780, the duc-
tal growth was greatly diminished and was comparable with
that of ovariectomy (Figure 1, compare b and e). However,
mammary glands of mice treated with ZK 98,299 (Figure 1f) or
with RU486 (Figure 1g) still exhibited side branching similar to
intact untreated mice.
Quantitation of the gross histological appearance confirmed
the absence of hyperplasias in mammary glands of ovariect-
omized PR-A transgenics or intact mice treated with ICI
182,780 and the prevalence of hyperplasias in mammary
glands of intact mice treated with RU486 or ZK 98,299, which
was similar to untreated intact mice (Figure 2). Likewise, treat-
ment of ovariectomized mice with estradiol alone, but not with
progesterone, led to a modest increase in the number of
hyperplasias; upon treatment with both estradiol and proges-
terone, however, hyperplasia prevalence was equivalent to
that seen in intact mice. These data suggest that estrogen and
progesterone have functionally distinct roles in hyperplasia.Breast Cancer Research    Vol 11 No 5    Simian et al.
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In parallel analyses for cell proliferation, BrdU-positive cells
were rarely detected in mammary glands of ovariectomized
mice, but increased upon treatment with estradiol into the
range seen in intact mice (Figure 3). Similar to ovariectomy,
BrdU-positive cells were infrequent in intact mice treated with
the antiestrogen ICI 182,780. The number of BrdU-positive
cells in both normal and hyperplastic ducts of intact mice
treated with ZK 98,299, however, was essentially similar to
that of untreated intact mice (Figure 3). Our earlier studies
have shown that antiprogestin, RU486, had no effect on cell
proliferation in the hyperplasias [9].
These observations established that a) the increase in cell pro-
liferation, a pre-requisite for the genesis of hyperplasias,
required signaling through estradiol/ER but was not sufficient
to give rise to overt hyperplasias in magnitude corresponding
to that seen in intact untreated PR-A mice; b) that while the
overexpression of PR-A leads to the development of the hyper-
plasias, cross-talk with ER is essential for the manifestation of
the hyperplastic phenotype; and c) that antiprogestins ZK
98,299 or RU486 were not sufficient to revert the hyperplastic
phenotype. On the whole, these data reveal that, in the context
of PR-A overexpression in the mouse mammary gland, the
requirement for estradiol and progesterone is mediated
through different mechanisms; however, these mechanisms
are interdependent.
TGF1 expression is impeded in mammary glands of PR-
A transgenic mice
In adult female mice, mammary epithelial cells are maintained
in a quiescent state in part due to the actions of TGF1 [14].
TGF1 is produced as a latent complex with LAP and needs
to be activated to exert its biological effect [15]. In the mam-
mary gland, activation of TGF1 is regulated by estradiol and
progesterone, and restricts the proliferative response to these
steroids [14]. The hyperproliferation of mammary epithelial
cells in PR-A transgenics is therefore possibly due to dimin-
ished expression and/or activity of TGF1. One of a few tools
available to assess TGF1 in situ is the double staining for
LAP and TGF1 epitopes that are revealed upon activation
[16].
Mammary glands of PR-A transgenics showed a statistically
significant decrease in both LAP and TGF1 as compared
with wild-type litter mate controls (Figure 4a, b). Mammary
development in PR-B transgenics is abnormal in that they have
a limited capacity for ductal elongation, in contrast to hyperpla-
sias exhibited by PR-A transgenics [6,7]. To determine
whether reduced expression of TGF1 associated with exces-
sive ductal growth in PR-A transgenics was specifically due to
overexpression of PR-A, we examined the expression patterns
of TGF1 in mammary glands of PR-B transgenics. Compared
with mammary glands of PR-A transgenics, both latent TGF1
and active TGF1 were present at a higher level in PR-B trans-
genics, although only the increase in LAP was statistically sig-
nificant (Figure 4c). Downregulation of total TGF1 mediated
by PR-A, in contrast to upregulation by PR-B, therefore prob-
ably mimics the Tgfb1 heterozygote phenotype of exaggerated
response to steroid hormone-mediated proliferation [17].
Figure 1
Whole mounts of mammary glands of adult mice carrying additional A form of PR Whole mounts of mammary glands of adult mice carrying additional A form of PR.  Whole mounts of mammary glands derived from (a) intact PR-A 
transgenic mice, (b) ovariectomized PR-A transgenic mice, (c) ovariectomized PR-A transgenic mice treated with estradiol 1 g for 5 days, (d) ova-
riectomized PR-A transgenic mice treated with estradiol 1 g and progesterone 1 mg for 5 days, (e) intact PR-A transgenic mice treated with ICI 
182,780 for 4 days, (f) intact PR-A transgenic mice treated with ZK98,299 for 4 days, and (g) intact PR-A transgenic mice treated with RU486 for 
4 days.Available online http://breast-cancer-research.com/content/11/5/R72
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Modulation of matrix metalloproteinase activity and 
basement membrane integrity by estrogen and 
progesterone
Side branching and alveolar morphogenesis requires remode-
ling of the BM [18]. We had previously shown discontinuous
laminin-1 staining in the mammary glands of PR-A transgenics
indicating a loss of BM integrity [6]. We show here that immu-
nostaining for laminin-5 and collagen IV was also discontinu-
ous. Furthermore, there was decreased collagen III
immunoreactivity in the stroma surrounding the regions with
aberrant epithelial structures (Figure 5a). Importantly, ovariec-
tomy restored the integrity of the BM as revealed by continu-
ous laminin-1 staining in PR-A mice (Figure 5b), and this effect
was reversed by administration of estrogen and progesterone
(Figure 5b). Upregulation of PR-A therefore appears to lead to
remodeling of the BM.
Remodeling of the ECM is regulated mainly by matrix metallo-
proteinases (MMPs), the expression of which is under devel-
opmental regulation in the mammary gland [19]. Furthermore,
targeted overexpression of MMP-3 (stromelysin-1) in mam-
mary epithelium leads to increased branching morphogenesis
[20], hyperplasia [21] and tumors [22]. To assess whether the
loss in BM integrity observed in the mammary glands of PR-A
transgenics was due to altered expression of MMPs, we exam-
ined the latent and active forms of MMPs by gelatin zymogra-
phy. As shown in Figure 6a, total tissue extracts of mammary
glands derived from either wild-type and PR-A mice revealed
three distinct bands corresponding to latent MMP-9, latent
MMP-2 and active MMP-2. Quantitation of the levels of total
MMP-2 (Figure 6a) and MMP-9 (data not shown) as deter-
mined by densitometry did not reveal a significant difference
between the mammary glands of wild-type mice and PR-A
transgenics. To further investigate whether there could be a
link between the total levels of PR and MMP activity, we ana-
lyzed tissue extracts derived from PR null mutant mice and
compared them with their littermate controls. As shown in Fig-
ure 6b, there was a statistically significant decrease in the lev-
els of total MMP-2 in the PR null mutant mice - suggesting that
the steady-state levels of PR modulate proteolytic activity in
the mouse mammary gland.
To determine whether signaling through ER and/or PR were
involved in modulating MMP activities, we analyzed tissue
Figure 2
Effects of hormonal treatments on hyperplasia prevalence in mammary  glands of PR-A transgenic mice Effects of hormonal treatments on hyperplasia prevalence in mammary 
glands of PR-A transgenic mice.  Five to six tissue sections, corre-
sponding to each group and representing mammary glands from two to 
three PR-A transgenic mice, were stained with H&E and a minimum of 
100 ducts per section were counted. Each mammary gland from each 
mouse was analyzed in duplicate. Data is presented as percentage of 
total ducts and represent the mean ± standard error of the mean. Ova-
riectomy led to a decrease in the percentage of hyperplasias (intact vs. 
ovariectomized (Ovx), *P  0.01), which was partially recovered by 
administration of estradiol (Ovx vs. Ovx+E, *P  0.01) and was com-
pletely recovered by treatment with estradiol 1 g and progesterone 1 
mg (Ovx vs. OvxE+P, *P  0.001). On the other hand, treatment with 
ICI 182,780 also led to a decrease in the percentage of hyperplasias 
(intact vs. intact+ICI 182,780, *P  0.001), but neither the antipro-
gestins RU486 or ZK 98,299 had an effect. Ovx+P, ovariectomized 
mouse treated with progesterone 1 mg.
Figure 3
5-Bromo-2-deoxyuridine labeling indices in mammary glands of PR-A  transgenic mice under various hormonal statuses 5-Bromo-2-deoxyuridine labeling indices in mammary glands of PR-A 
transgenic mice under various hormonal statuses.  Percentage of 5-
bromo-2-deoxyuridine (BrdU)-positive mammary epithelial cells of nor-
mal ducts (ND) and hyperplastic ducts (HD) of PR-A transgenics under 
various hormonal statuses. Data presented as the mean ± standard 
error of the mean. Mammary glands from a minimum of three mice were 
examined, and mammary glands for each mouse were analyzed in tripli-
cate. In each experiment, the percentage of immunopositive cells was 
obtained by counting a minimum of 500 cells per gland. Ovx, ovariect-
omized mouse; Ovx+E, ovariectomized mouse treated with estradiol 1 
g.Breast Cancer Research    Vol 11 No 5    Simian et al.
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extracts of ovariectomized mice exposed to exogenous estro-
gen and/or progesterone (Figure 6c). Mammary glands of
wild-type mice treated with estrogen and progesterone exhib-
ited statistically significant increased levels of active MMP-2
(Figure 6c). This increase did not occur in the glands derived
from animals treated with either estrogen or progesterone
alone. As with wild-type mice, MMP-2 activation was observed
in mammary glands of ovariectomized PR-A mice treated with
estrogen and progesterone; again estrogen alone did not have
any effect on the levels of active MMP-2 (data not shown). Pro-
gesterone alone, however, elicited MMP-2 activation in PR-A
transgenics (Figure 6d).
To detect MMP activity within the tissue it is necessary to use
a tool that can distinguish between the latent and active forms.
We used an antibody that specifically detected latent MMP-2
and does not cross-react with its active form. We correlated
the localization of latent MMP-2 to that of laminin-5 staining,
which has been previously shown to be degraded by MMP-2
[23]. In mammary glands of wild-type mice, and in regions
where the ducts appeared normal in PR-A transgenics, latent
MMP-2 and laminin-5 were detected in the periepithelial
stroma (Figure 7a). In regions with aberrant structures, how-
ever, latent MMP-2 was either reduced or dramatically absent
and laminin-5 was essentially degraded. These observations
that hyperplasias in the mammary glands of PR-A transgenics
have increased MMP activity and increased BM degradation
support the hypothesis that PR-A drives MMP-2 activation.
Finally, to exclude the possibility that the degradation of the
BM was specifically due to overexpression of PR-A and was
not the result of the overall imbalance in the ratio of the two iso-
forms of PR, we carried out laminin-1 staining in mammary
glands of PR-B mice. As shown in Figure 7b, the basement
membrane was intact in PR-B mice.
Discussion
We have previously shown that mammary gland development
in PR-A transgenic mice is abnormal, characterized by exten-
sive ductal growth, lateral branching and loss of basement
membrane integrity and cell-cell adhesion [6]. In the present
report we show that the proliferative phenotype of PR-A mice
is dependent on ovarian steroids, where hyperplasia is medi-
ated by distinct mechanisms. PR-A transgenic expression aug-
ments ER- mediated proliferation while PR-A the degradation
of the basement membrane, both essential requirements for
the development of hyperplasias. Moreover, even though pro-
gesterone is required for the manifestation of the hyperplasias,
antiprogestins have no effect on the established hyperplastic
phenotype.
Signaling through estradiol/ER is required for proliferation, but
is not enough to give rise to overt hyperplasias. Once estab-
lished, these hyperplasias are dependent on ER signaling,
since treatment with the antiestrogen ICI 182,780 abolishes
Figure 4
Transforming growth factor beta 1 and latency-associated peptide in  PR-A and PR-B mice mammary glands Transforming growth factor beta 1 and latency-associated peptide in 
PR-A and PR-B mice mammary glands.  (a) Examples of dual immun-
ofluorescence staining to latency-associated peptide (LAP) (green) and 
transforming growth factor beta 1 (TGF1) (red) in mammary glands 
derived from wild-type (WT) and PR-A transgenic mice; both were 
decreased in the transgenic mice. Nuclei were counterstained with 
4',6-diamino-2-phenylindole (DAPI). (b) Quantitative image analysis of 
the intensity of LAP and TGF1 immunoreactivity per cell in mammary 
glands of PR-A mice. Both LAP and TGF1 had a lower intensity in 
cells derived from PR-A transgenic mice as compared with WT con-
trols (P < 0.001 in both cases). (c) Quantitative image analysis of the 
intensity of LAP and TGF1 immunoreactivity per cell in PR-A mice ver-
sus PR-B mice. Only the increase in LAP in PR-B mice compared with 
PR-A mice was statistically significant (P < 0.001). The difference in 
active TGF1, although increased in PR-B mice, was not statistically 
significant.Available online http://breast-cancer-research.com/content/11/5/R72
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them; we have not determined, however, the relative role of
ER and ER. On the other hand, the overexpression of PR-A
leads to antiprogestin resistance, since neither ZK 98,299 nor
RU486 had any effect on the expression of the hyperplasia in
the intact mice. Both antiprogestins have similar mechanisms
of action inducing PR binding to the DNA, but causing confor-
mational changes that block co-activator binding to the recep-
tor, thus making it transcriptionally inactive [24]. The
antagonistic activity in both cases, however, has been shown
to depend on the cellular context that determines the degree
of the antagonist/agonist activity of these compounds, which
relies on the balance between expression and availability of
coactivators and corepressors and the context of specific tar-
get promoters available in any given cell type [24]. Further-
more it is clear from the ovariectomized mice that
progesterone is necessary to induce the full phenotype. Over-
expression of PR-A in the mouse mammary gland therefore
seems to generate a cellular context that promotes hyperpla-
sia, but whose maintenance is not dependent on progesterone
signaling per se.
The hyperproliferation observed in the mammary glands of PR-
A transgenic mice may be due to the diminished expression
found for both latent and active TGF1. Activation of TGF1
is regulated by estradiol and progesterone, which in turn
restricts the proliferative response to these steroids [14]. Our
studies suggest that physiological estradiol drives inhibition of
TGF1 that in turn increases proliferation in response to estra-
diol, which is consistent with its action in estrus shown using
TGF1 heterozygote mice [17]. Notably, the mammary glands
of Tgfb1 heterozygote mice are two to four times more prolif-
erative yet there is no evidence of hyperplasia [17]. While sim-
ilar to Tgfb1 with regards to decreased TGF1 levels and
increased proliferative response to steroid hormones, an addi-
tional action of PR-A must therefore be necessary for the
expression of hyperplasia.
Since our studies show that signaling through progesterone
has no impact on proliferation in hyperplastic PR-A mice but is
required for the manifestation of the hyperplasias, we postu-
lated that another effect must be required. We show that sig-
naling through PR modulates the activation of MMP-2, and
that areas of BM disruption coincide with loss of latent MMP-
2. The integrity of BMs is dictated by the composition of
MMPs, their inhibitors and the status of their activation [25].
MMPs have been shown to be key regulators of branching
morphogenesis in the mouse mammary gland [20,26,27]. On
the other hand it has long been known that both estrogen and
progesterone affect mammary gland development regulating
ductal elongation, side branching and differentiation. The
development of PR and ER transgenic and knockout mice in
the past decade has provided additional evidence to confirm
these results [4,6,28]. To date, however, there is insufficient
evidence to address the intriguing question of how hormonal
action, MMP production and activation are linked in the mouse
mammary gland.
We have previously shown that there was loss of laminin-1 in
areas of aberrant epithelial morphology in PR-A transgenic
mice [6]. We now report that, in addition to laminin-1, immuno-
reactivity of laminin-5, collagen IV and collagen III is also lost.
In the mammary glands of PR-A transgenics, therefore, the
Figure 5
Basement membrane disruption in mammary glands of PR-A transgenic mice: regulation by ovarian hormones Basement membrane disruption in mammary glands of PR-A transgenic mice: regulation by ovarian hormones.  (a) Laminin-5 (LN-5), collagen IV 
(CoIV) and collagen III (CoIII) immunoreactivity (green) circumscribed the mammary epithelium of wild-type (WT) mice, but were decreased in the 
glands of PR-A transgenic mice. Nuclei were counterstained with 4',6-diamino-2-phenylindole (blue). (b) Ovariectomy (Ovx) of PR-A mice led to a 
recovery of the basement membrane integrity as shown by the continuous laminin staining. Upon treatment with estrogen 1 g and progesterone 1 
mg for 4 days (OvxE+P), however, the staining was lost.Breast Cancer Research    Vol 11 No 5    Simian et al.
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Figure 6
Matrix metalloproteinases in mammary glands of adult wild-type and PR-A transgenic mice analyzed by zymography Matrix metalloproteinases in mammary glands of adult wild-type and PR-A transgenic mice analyzed by zymography.  (a) Zymogram of protein 
extracts prepared from mammary glands of two PR-A mice, and a littermate control (WT). Graph shows comparison of the levels, estimated by laser 
densitometry, of total MMP-2 in transgenic mice (n = 5) and littermate control mice (n = 3). No statistically significant differences were found. Similar 
results were obtained for MMP-9 (data not shown). (b) Zymogram of protein extracts prepared from mammary glands of two PR null mutant mice 
(PR-/-), and a littermate control (WT). Graph shows comparison of the levels, estimated by laser densitometry, of total MMP-2 in PR-/- mice (n = 5) 
and littermate control mice (n = 4). There was a statistically significant reduction in the total levels of MMP-2 in the PR null mutant mice (P  0.01). 
(c) Representative zymograms showing activation of MMP-2 in wild-type mice only when they were treated with estrogen and progesterone. Repre-
sentation of the mean ± standard error of the mean corresponding to the densitometric values of active MMP-2 in ovariectomized mice (Ovx, n = 6), 
ovariectomized mice treated with E (Ovx+E, n = 4), ovariectomized mice treated with P (Ovx+P, n = 3) and ovariectomized mice treated with estro-
gen and progesterone (Ovx+E+P, n = 3). In all cases, values were normalized to controls that were considered equal to 1. The increase in the levels 
of active MMP-2 were statistically significant in Ovx+E+P compared with Ovx (P  0.001), Ovx+E (P  0.05) and Ovx+P (**P  0.01). (d) Zymogram 
and densitometric analysis of mean ± standard error of the mean showing activation of MMP-2 by progesterone in ovariectomized PR-A mice 
(Ovx+P, n = 2) compared with ovariectomized mice (Ovx, n = 2). The increase in active MMP-2 activity was statistically significant (*P  0.05). 
AMMP, active matrix metalloproteinase; LMMP, latent matrix metalloproteinase; n, number of glands analyzed from different mice.Available online http://breast-cancer-research.com/content/11/5/R72
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concurrent loss of laminin and collagen indicate that the ECM
is broadly affected. More importantly the fact that the pheno-
type was reversible by ovariectomy points to a role for hormo-
nal action in the maintenance of ECM integrity, which is
supported by our observation that the administration of estra-
diol and progesterone to ovariectomized PR-A transgenic
mice led to BM degradation, strongly supporting this notion.
Alterations in the mammary gland ECM have been previously
described in transgenic mice expressing an active form of
MMP-3 in the epithelium [21]. The fact that total MMP-2 levels
in extracts derived from PR-A transgenic mice were not signif-
icantly different could be due to the heterogeneous pheno-
type, as previously shown [6], and is consistent with the
statistically significant decrease we observed in MMP-2 levels
only in PR null mutant mice. Moreover, immunolocalization
studies support the notion of a restricted phenotype as we
found decreased latent MMP-2 only in hyperplastic regions
where laminin-5 was absent.
The finding that treatment of ovariectomized wild-type mice
with estradiol and progesterone leads to the activation of
MMP-2 is the first direct demonstration that hormonal action
modulates MMP activity in the mouse mammary gland. This
result suggests an important role for MMP-2 during prolifera-
tion and differentiation that takes place during pregnancy. It is
significant to note that while in wild-type ovariectomized mice
progesterone alone had no effect on MMP-2 activation
(because there is little or no PR-A), it caused an increase in the
activation of MMP-2 in mammary glands of ovariectomized PR-
A transgenics because they still expressed a high level of PR-
A. In wild-type mice, ER would therefore be necessary to sup-
port the levels of PR, but signaling through PR-A would be
important for the activation of MMP-2.
Using MMP-2 knockout mice, Wiseman and collaborators
have shown that during puberty MMP-2 positively regulates
invasion of terminal end buds but that it inhibits side branching
from mature ducts. They also postulated TGF1 as the candi-
date for the inhibitory action of MMP-2 on lateral branching at
puberty [26]. This speculation is supported by recent mode-
ling studies that demonstrate the effect of TGF1 as a branch-
ing inhibitor [29]. In mammary glands of PR-A transgenics
there is a positive relationship between the steroid hormone-
dependent increase in MMP-2 activity and lateral branching,
accompanied by a reduction in both the latent and active
forms of TGF1. It is possible that other proteases are also
involved, however, given that, although statistically significant,
the degree of activation of MMP-2 was modest both in the
wild-type and in the PR-A transgenics.
Given that MMP-2 is expressed by the periductal stroma and
weakly by the adipose tissue [26], and that PR is expressed
exclusively in the epithelial compartment [30], cross-talk
Figure 7
MMP-2/laminin-5 in mammary glands of adult wild-type and PR-A mice; laminin immunostaining in PR-B transgenics MMP-2/laminin-5 in mammary glands of adult wild-type and PR-A mice; laminin immunostaining in PR-B transgenics.  In situ localization of MMP-2 
and laminin-5 in mammary glands of adult wild-type (WT) and PR-A transgenics, and laminin staining in PR-B transgenics. (a) MMP-2 and laminin-5 
were detected in fixed frozen sections of mammary glands, using an indirect immunofluorescence assay, as described in the text. Blue, 4',6-diamino-
2-phenylindole (DAPI) staining of the nuclei; green, fluorescein isothiocyanate staining corresponding to immunoreactive latent MMP-2; red, Texas 
Red staining corresponding to immunoreactive laminin-5. Staining in glands from WT mice and in normal structures derived from PR-A mice showed 
continuous laminin-5 staining and the presence of MMP-2 in the periepithelial stroma. In aberrant structures derived from glands of PR-A transgenic 
mice, however, staining for both laminin-5 and latent MMP-2 was lost (right panels). Top left, mammary duct from wild-type mouse; bottom left, nor-
mal duct from PR-A transgenic mouse; top right, duct from PR-A transgenic mouse containing both normal and morphogenetically disturbed epithe-
lium; bottom left, aberrant structure in PR-A transgenic mouse. (b) Laminin staining (green) in a mammary gland derived from a PR-B transgenic 
mouse shows that it circumscribes the epithelium as in the WT control. Nuclei were counterstained with DAPI (blue).Breast Cancer Research    Vol 11 No 5    Simian et al.
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between both compartments seems to be a necessary condi-
tion for MMP-2 activation. A possible mediator of this cross-
talk may be MT1-MMP, which is expressed both by the stroma
and the epithelium [26]. This hypothesis is supported by the
fact that we have detected an increase in the levels of MT1-
MMP in the mammary glands of pregnant mice, and that MT1-
MMP levels were high in certain areas in mammary glands of
PR-A transgenic mice (Simian M and Shyamala G, unpub-
lished observations). Additionally, degradation of collagen IV
appears to require the action of MT1-MMP [31]. Whether PR-
positive cells are also MT1-MMP-positive remains to be
determined.
Conclusions
An imbalance in the relative ratio of PR-A and PR-B isoforms
has been observed in certain human mammary tumors, and
this is often associated with overexpression of the PR-A form
[32-34]. Our studies show that this imbalance has a direct
impact on three major phenomena underlying mammary biol-
ogy - that is, steroid hormone responsiveness, TGF1 produc-
tion, and ECM remodeling mediated by MMP activity - all of
which are implicated in mammary epithelial cell transformation.
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